Cargando…

Modern Management and Diagnostics in HER2+ Breast Cancer with CNS Metastasis

SIMPLE SUMMARY: HER2-positive breast cancer has an affinity for the central nervous system (CNS) manifested by metastases in both the brain parenchyma and the leptomeninges. The authors review the epidemiology of HER2-positive CNS metastases, risk factor, and prognosis herein. They also discuss avai...

Descripción completa

Detalles Bibliográficos
Autores principales:	Warrior, Surbhi, Cohen-Nowak, Adam, Kumthekar, Priya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251820/ https://www.ncbi.nlm.nih.gov/pubmed/37296873 http://dx.doi.org/10.3390/cancers15112908

Ejemplares similares

Updates on Molecular Targeted Therapies for Intraparenchymal CNS Metastases
por: Sharma, Akanksha, et al.
Publicado: (2021)

SDPS-10 DISPARITIES IN THE RISK OF CNS METASTASIS AND CLINICAL OUTCOMES IN PATIENTS WITH HER2- MUTATION POSITIVE (HER2+) NON-BREAST VERSUS HER2+ BREAST CANCERS
por: Elghawy, Omar, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors for the Treatment of Central Nervous System (CNS) Metastatic Disease
por: Kamath, Suneel D., et al.
Publicado: (2018)

Pertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA final efficacy data
por: Lin, Nancy U., et al.
Publicado: (2023)

HER-2/neu diagnostics in breast cancer
por: Carney, Walter P, et al.
Publicado: (2007)

SDPS-20 THE HER2 FLIP: HER2 AMPLIFICATION OF TUMOR CELLS IN THE CEREBROSPINAL FLUID (CSF-TCS) OF PATIENTS WITH LEPTOMENINGEAL METASTASIS HAVING SOLID TUMORS; IMPLICATIONS FOR TREATING THE LM TUMOR WITH ANTI-HER2 THERAPY
por: Kumthekar, Priya, et al.
Publicado: (2023)

Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study
por: Lin, Nancy U., et al.
Publicado: (2021)

Appendicitis caused by the metastasis of HER2-positive breast cancer
por: Mori, Ryutaro, et al.
Publicado: (2016)

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
por: Majumder, Avisek, et al.
Publicado: (2021)

SDPS-46 CENTRAL NERVOUS SYSTEM (CNS)-RELATED MORTALITY IN PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER
por: Ferraro, Emanuela, et al.
Publicado: (2023)

Concordance of breast cancer biomarker testing in core needle biopsy and surgical specimens: A single institution experience
por: Slostad, Jessica A., et al.
Publicado: (2022)

29. ROLE OF AGE AND CNS MYELOID CELLS ON BREAST CANCER BRAIN METASTASIS
por: Lai Wu, Alex Man, et al.
Publicado: (2020)

ATM-Inhibitor AZD1390 Is a Radiosensitizer for Breast Cancer CNS Metastasis
por: Tew, Ben Yi, et al.
Publicado: (2023)

BSLD-01 DYNAMIC CONTROL OF CSF FOR PERSONALIZED CNS DRUG DELIVERY FOR LEPTOMINGEAL DISEASE
por: Kumthekar, Priya, et al.
Publicado: (2023)

Complete pathologic response of HER2-positive breast cancer liver metastasis with dual Anti-HER2 antagonism
por: Schoellhammer, Hans F, et al.
Publicado: (2014)

Impact of Treatment and Anticoagulation on Thrombosis in COVID-19 Patients
por: Warrior, Surbhi, et al.
Publicado: (2020)

Advances in the diagnosis, evaluation, and management of leptomeningeal disease
por: Sener, Ugur, et al.
Publicado: (2021)

HIV-Associated CNS Vasculopathy in the Modern Era
por: Chang, Gregory Youngnam
Publicado: (2017)

Factors affecting time to brain metastases for stage 2 and 3 breast cancer patients: A large single-institutional analysis with potential screening implications
por: Cao, Toni Q, et al.
Publicado: (2021)

LPTO-02. INTRATHECAL (IT) TRASTUZUMAB (T) FOR THE TREATMENT OF LEPTOMENINGEAL DISEASE (LM) IN PATIENTS (PTS) WITH HUMAN EPIDERMAL RECEPTOR-2 POSITIVE (HER2+) CANCER: A MULTICENTER PHASE 1/2 STUDY
por: Kumthekar, Priya, et al.
Publicado: (2019)

Discordances in ER, PR, and HER2 between primary breast cancer and brain metastasis
por: Jung, Jaehag, et al.
Publicado: (2017)

HER2‐positive breast cancer brain metastasis: A new and exciting landscape
por: Zimmer, Alexandra S., et al.
Publicado: (2020)

HER2+ breast cancer treatment and cardiotoxicity: monitoring and management
por: Jerusalem, Guy, et al.
Publicado: (2019)

Diagnostics and Therapeutics in Targeting HER2 Breast Cancer: A Novel Approach
por: Vi, Chris, et al.
Publicado: (2021)

Efficacy of a HER2-Targeted Thorium-227 Conjugate in a HER2-Positive Breast Cancer Bone Metastasis Model
por: Karlsson, Jenny, et al.
Publicado: (2023)

WASF3 provides the conduit to facilitate invasion and metastasis in breast cancer cells through HER2/HER3 signaling
por: Teng, Yong, et al.
Publicado: (2016)

Diagnostic value of core needle biopsy for determining HER2 status in breast cancer, especially in the HER2-low population
por: Chen, Ruixian, et al.
Publicado: (2022)

GM-CSF - an oncogenic driver of HER2+ breast leptomeningeal metastasis
por: Garg, Rachana, et al.
Publicado: (2022)

Effective Treatment of Solitary Pituitary Metastasis with Panhypopituitarism in HER2-Positive Breast Cancer by Lapatinib
por: Park, Youngmok, et al.
Publicado: (2016)

Liquid biopsy for HER2-positive breast cancer brain metastasis: the role of the cerebrospinal fluid
por: De Mattos-Arruda, Leticia
Publicado: (2017)

Liver resection for HER2-enriched breast cancer metastasis: case report and review of the literature
por: Temukai, Mai, et al.
Publicado: (2017)

Follistatin is a metastasis suppressor in a mouse model of HER2-positive breast cancer
por: Seachrist, Darcie D., et al.
Publicado: (2017)

FABP7 is a key metabolic regulator in HER2+ breast cancer brain metastasis
por: Cordero, Alex, et al.
Publicado: (2019)

Poziotinib Inhibits HER2-Mutant–Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer
por: Kalra, Rashi, et al.
Publicado: (2022)

HER2 status of CTCs by peptide-functionalized nanoparticles as the diagnostic biomarker of breast cancer and predicting the efficacy of anti-HER2 treatment
por: Wang, Mengting, et al.
Publicado: (2022)

Impact of Blood Group Type on Severity of Disease in COVID-19 Patients
por: Rao, Shivani, et al.
Publicado: (2020)

Heparin Induced Thrombocytopenia in Patients with COVID-19
por: Warrior, Surbhi, et al.
Publicado: (2020)

Current approaches to the management of Her2-negative metastatic breast cancer
por: Gogineni, Keerthi, et al.
Publicado: (2012)

New Agents for the Management of Advanced HER2-Positive Breast Cancer
por: Royce, Melanie, et al.
Publicado: (2016)

Breast Cancer and Her-2/Neu
por: Sherwood, Roy
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_u27ud9i2j3gphkhah09208uht4